Jazz Pharmaceuticals plc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Jazz Pharmaceuticals plc (JAZZ) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -1.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-24
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -1.40%.
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2020 was 3.10%, a 72.22% increase from fiscal 2019.
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2019 was 1.80%, a 50.00% increase from fiscal 2018.
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2018 was 1.20%, a 53.85% decline from fiscal 2017.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | -1.40% 10-K · filed 2026-02-24 |
| 2020-12-31 | 3.10% 10-K · filed 2021-02-23 |
| 2019-12-31 | 1.80% 10-K · filed 2021-02-23 |
| 2018-12-31 | 1.20% 10-K · filed 2021-02-23 |
| 2017-12-31 | 2.60% 10-K · filed 2020-02-25 |
| 2016-12-31 | 1.80% 10-K · filed 2019-02-26 |
| 2015-12-31 | 1.90% 10-K · filed 2018-02-27 |
| 2014-12-31 | 4.60% 10-K · filed 2017-02-28 |
| 2013-12-31 | 1.30% 10-K · filed 2016-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |